Diabetes Mellitus Archives - Medical Conferences

BPROAD: Intensive or standard BP treatment strategy in type 2 diabetes?

Presented By

Prof. Guang Ning, Shanghai Jiao Tong University School of Medicine, China

Trial

BROAD

Conference

AHA 2024

Type

News article

18 November 2024 12:22

Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes

Presented By

Dr Uffe Heide-Jørgensen, Aarhus University, Aarhus, Denmark

Conference

ERA 2024

Type

News article

20 June 2024 19:09

FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease

Presented By

Prof. Vlado Perkovic, University of New South Wales, Sydney, Australia

Trial

Phase 3, FLOW

Conference

ERA 2024

Type

News article

20 June 2024 18:19

Early phase data show albuminuria improvement with avenciguat

Presented By

Prof. Hiddo J.L. Heerspink, University Medical Center Groningen, The Netherlands

Conference

ERA 2024

Type

News article

20 June 2024 18:17

Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes

Presented By

Dr Joseph Stavas, ProKidney LLC, Winston-Salem, NC, USA

Trial

Phase 2, REACT

Conference

ERA 2024

Type

News article

20 June 2024 18:13

STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes

Presented By

Prof. Mikhail Kosiborod, Saint Luke's Mid America Heart Institute, MO, USA

Trial

Phase 3, STEP-HFpEF DM

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:20

SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?

Presented By

Allison Holt, UMass Chan Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:06

Pemafibrate reduces microvascular complications of PAD and T2D

Presented By

Dr Aruna Pradhan, Brigham and Women’s Hospital, USA

Trial

Phase 3, PROMINENT

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:39

Interview: Medicare’s first drug price negotiations: concerning?

Expert

Prof. Marc Bonaca, University of Colorado, USA

4 January 2024 15:06

Heart failure: the 2023 update

Presented By

Prof. Theresa McDonagh; Prof. Roy Stuart Gardner; Prof. Alexandre Mebazaa; Prof. Ewa Jankowska; Prof. Marianna Adamo

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:05

Cardiovascular disease and diabetes: new guidelines

Presented By

Prof. Emanuele Di Angelantonio; Prof. Nikolaus Marx; Dr Katharina Schuett; Prof. Dirk Müller-Wieland; Prof. Bianca Rocca

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:02

High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes

Presented By

Dr Mathis Mottelson, Copenhagen University Hospital, Denmark

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:05

Multifaceted strategy improves prescription of therapies for diabetes and ASCVD

Presented By

Prof. Neha Pagidipati, Duke University Hospital, NC, USA

Trial

COORDINATE-Diabetes

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:55

Digitally delivered cognitive behavioural therapy successful in type 2 diabetes

Presented By

Prof. Marc Bonaca, University of Colorado, CO, USA

Trial

Phase 3, BT-001

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:00

Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver

Presented By

Dr Aruna Pradhan, Brigham and Women’s Hospital, MA, USA

Trial

Phase 3, PROMINENT

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 13:46

Diabetes not related to abnormal biomarkers of Alzheimer’s disease

Presented By

Veerle van Gils, Maastricht University, the Netherlands

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 10:53

FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status

Presented By

Prof. Gerasimos Filippatos , Attikon University Hospital, Greece

Trial

Phase 3, FIDELIO-DKD, FIGARO-DKD

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 12:09

Sotagliflozin SCORED MACE benefit

Presented By

Prof. Deepak Bhatt, Brigham and Women's Hospital, USA

Trial

Phase 3, SCORED

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:57

Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes

Presented By

Dr Ameenathul Fawzy, Liverpool Heart and Chest Hospital, UK

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 11:03

High treatment success with ixekizumab in patients with psoriasis and diabetes

Presented By

Dr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark

Trial

Phase 3, UNCOVER

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:15

CHIEF-HF: Canagliflozin improves health status in heart failure

Presented By

Prof. John Spertus, University of Missouri-Kansas City, USA

Trial

Phase 3, CHIEF-HF

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:59

Therapeutic approaches in heart failure with diabetes

Presented By

Prof. Lynne Stevenson, Vanderbilt University Medical Center, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:48

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December 2021 08:12

VOYAGER PAD: Fragile or diabetic patients also benefit from rivaroxaban

Presented By

Prof. Cecilia Low Wang, University of Colorado, USA

Trial

VOYAGER PAD

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:24

Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD

Presented By

Prof. Bertram Pitt, University of Michigan School of Medicine, USA

Trial

Phase 3, FIGARO-DKD

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:40

2021 ESC Guidelines on Heart Failure

Presented By

Prof. Carolyn Lam, Duke-NUS Medical School, Singapore

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:34

2021 ESC Guidelines on Cardiovascular Disease Prevention

Presented By

Prof. Frank Visseren, Guidelines Task Force Chair

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 11:52

Novel mineralocorticoid receptor antagonist effective irrespective of HF history

Presented By

Prof. Gerasimos Filippatos, Attikon University Hospital, Greece

Trial

FIDELIO-DKD

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 16:05

Empagliflozin linked to lower cardiovascular risk and renal events in real-world study

Presented By

Prof. Leo Niskanen, University of Eastern Finland, Finland

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:43

Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status

Presented By

Prof. Faiez Zannad, University of Lorraine, France

Trial

EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:39

Biomarker panel predicts SGLT2 inhibitor response

Presented By

Dr Muthiah Vaduganathan, Brigham and Women´s Hospital, MA, USA

Trial

CANVAS

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:33

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By

Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:53

Finerenone reduces the risk of AF onset in patients with CKD and diabetes

Presented By

Prof. Gerasimos Filippatos, Attikon University Hospital, Greece

Trial

Phase 3, FIDELIO-DKD

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 13:46

Obesity: A risk factor for new-onset asthma and worse asthma control

Presented By

Prof. Fernando Holguin, University of Colorado Asthma Research and Education, CO, USA

Trial

Cohort study, CARDIA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:52

No increased risk of (severe) COVID-19 among IBD patients

Presented By

Dr Vered Richter , Tel Aviv University, Israel

Conference

ECCO 2021

Type

News article

2 July 2021 23:52

Finerenone lowers CV events in diabetic CKD patients

Presented By

Prof. Gerasimos Filippatos, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, FIDELIO-DKD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:33

Dapagliflozin reduces renal risk independent of CV disease status

Presented By

Prof. John McMurray, University of Glasgow, Scotland

Trial

DAPA-CKD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:18

“Strongly consider an SGLT2-inhibitor in most T2DM patients”

Presented By

Prof. Deepak Bhatt, Brigham and Women’s Hospital, USA

Trial

Phase 3, SOLOIST-WHF; SCORED

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:14

2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines

Presented By

Prof. Antonio Pelliccia, Institute of Sports Medicine and Science, Italy

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:53

SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients

Presented By

Dr Milton Packer, Baylor University Medical Center, USA

Trial

Phase 3, EMPEROR-Reduced trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:40

DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes

Presented By

Prof. Hiddo Heerspink, University of Groningen, the Netherlands

Trial

DAPA-CKD trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:23

Antisense ANGPTL3 lowers triglycerides

Presented By

Prof. Daniel Gaudet, University of Montréal, Canada

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:50

SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

Presented By

Prof. Francesco Cosentino, Karolinska University Hospital, Sweden

Trial

VERTIS CV

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:39

The Yale COVID-19 Cardiovascular Registry

Presented By

Dr Manan Pareek, Yale University School of Medicine, USA

Trial

Yale COVID-19 Cardiovascular Registry

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:24

TWILIGHT sub-study: same outcomes for diabetes patients

Presented By

Prof. D. Angiolillo, University of Florida - Jacksonville, USA

Trial

TWILIGHT, TWILIGHT-DM

Conference

ACC 2020

Type

Peer-reviewed article

8 September 2020 15:24

DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status

Presented By

Prof. John J. McMurray & Prof. Felipe A. Martinez

Trial

Phase 3, DAPA-HF

Conference

AHA 2019

Type

Peer-reviewed article

26 February 2020 19:16

Phase 3 BETonMACE trial did not meet its primary endpoint

Presented By

Prof. Kausik K. Ray, Imperial College London, United Kingdom

Trial

Phase 3, BETonMACE

Conference

AHA 2019

Type

Peer-reviewed article

26 February 2020 15:47

New guidelines on the prevention of cardiovascular conditions

Presented By

Prof. Roger S. Blumenthal, Johns Hopkins University, USA

Conference

AHA 2019

Type

Peer-reviewed article

26 February 2020 14:36

DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups

Conference

ACC 2019

Type

Peer-reviewed article

4 June 2019 14:16

Penile prosthesis implantation

Presented By

Dr Mahmoud Osman, Dr Mohamad Habous, Prof. Thomas Ahlering , Dr Frederico Dehò

Trial

PHOENIX

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 12:50